

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE  
02 FEB 14 PM 3:33

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Skadden, Arps, Slate, Meagher & Flom LLP			
2. Address <input type="checkbox"/> Check if different than previously reported 1440 New York Avenue, N.W. Washington, D.C. 20005			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country) _____			
4. Contact Name Brian D. Flynn	Telephone (202)371-7144	E-mail (optional)	5. Senate ID # 35560-19
7. Client Name <input type="checkbox"/> Self GlaxoSmithKline	6. House ID # 3170602		

**TYPE OF REPORT** 8. Year 2001 Midyear (January 1-June 30)  OR Year End (July 1-Dec)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇒ Termination Date \_\_\_\_\_

11. No Lobbying

## INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p align="center"><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>20,000</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center"><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$20,000)</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definit</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 603 Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162 Internal Revenue Code</p>
--	--

Signature \_\_\_\_\_

Printed Name and Title



Registrant Name Skadden, Arps, Slate, Meagher & Flom Client Name GlaxoSmithKline

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues  
Metered Dose Inhaler Transition Issues

17. House(s) of Congress and Federal agencies contacted  Check if None  
U.S. House of Representatives  
U.S. Senate  
EPA  
FDA  
State Department

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
James A. Losey	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None  
GlaxoSmithKline, Inc., owned by GlaxoSmithKline PLC, sells pharmaceutical products in the U.S. and abroad ensure transition policy for MDIs that protect patient and physician access to essential medical treatment options

Signature *James A. Losey* Date 2-12-07  
Printed Name and Title James A. Losey, Partner

